EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC 4.0

Low Tumor Burden Predicts Benefit from Transarterial Treatment in Hepatocellular Carcinoma with Extrahepatic Metastasis: A Nationwide Cohort Study

Jaejun Lee, Hyun Yang, Keungmo Yang, Ji Won Han, Pil Soo Sung, Jeong Won Jang, Si Hyun Bae

Liver Cancer · 03.03.2026 · 1-13

DOI: 10.1159/000551158 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Liver Cancer, online erschienen am 03.03.2026. Verfasst von Jaejun Lee und 6 weiteren Autor:innen. Beteiligte Einrichtung: The Catholic University Liver Research Center, Department of Biomedicine and Health Sciences, College of Medicine, The Catholic University of Korea, …. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Aims: In patients with hepatocellular carcinoma (HCC) and extrahepatic metastasis (EHM), intrahepatic disease control may remain clinically relevant in selected cases. This study aimed to compare survival outcomes between transarterial treatment (TAT) and systemic therapy (ST) as initial treatment.

Methods

Data from the Korean Central Cancer Registry (2008–2020) were analyzed. TAT included chemoembolization, radioembolization, and hepatic arterial infusion chemotherapy. Systemic therapy consisted predominantly of tyrosine kinase inhibitors (>98%). Overall survival (OS) was the primary endpoint. Propensity score matching (PSM) and inverse probability of treatment weighting (IPTW) adjusted for confounding.

Results

Among 19,753 treatment-naïve HCC patients, 2,517 had EHM. Of these, 663 received TAT and 595 received ST as initial therapy. In the overall cohort, TAT was associated with significantly longer OS than ST (median OS: 6.7 vs. 3.7 months, p < 0.001), and this benefit remained in both PSM and IPTW analyses (p < 0.001 for both). The advantage of TAT persisted across subgroups defined by metastatic site, number of metastatic organs, portal vein tumor thrombosis (PVTT), and tumor size, although the difference narrowed in tumors >10 cm. Multivariable analysis identified TAT, single-organ metastasis, alpha-fetoprotein

Schlagwörter

Stichwörter der Autor:innen

Extrahepatic metastasisHepatocellular carcinomaOverall survivalSystemic therapyTransarterial treatment

Autor:innen und Institutionen

  • The Catholic University Liver Research Center, Department of Biomedicine and Health Sciences, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
  • Division of Hepatology, Department of Internal Medicine, Eunpyeong St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
  • Division of Hepatology, Department of Internal Medicine, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
  • Division of Hepatology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.

Zitieren

APA

Lee, J., Yang, H., Yang, K., Han, J. W., Sung, P. S., Jang, J. W., & Bae, S. H. (2026). Low Tumor Burden Predicts Benefit from Transarterial Treatment in Hepatocellular Carcinoma with Extrahepatic Metastasis: A Nationwide Cohort Study. Liver Cancer, 1-13. https://doi.org/10.1159/000551158

Vancouver

Lee J, Yang H, Yang K, Han JW, Sung PS, Jang JW, et al. Low Tumor Burden Predicts Benefit from Transarterial Treatment in Hepatocellular Carcinoma with Extrahepatic Metastasis: A Nationwide Cohort Study. Liver Cancer. 2026:1-13. doi:10.1159/000551158

BibTeX
@article{Lee2026,
  author = {Lee, Jaejun and Yang, Hyun and Yang, Keungmo and Han, Ji Won and Sung, Pil Soo and Jang, Jeong Won and Bae, Si Hyun},
  title = {Low Tumor Burden Predicts Benefit from Transarterial Treatment in Hepatocellular Carcinoma with Extrahepatic Metastasis: A Nationwide Cohort Study},
  journal = {Liver Cancer},
  year = {2026},
  pages = {1--13},
  doi = {10.1159/000551158}
}
Kostenlos starten →